Reyataz
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost (cobicistat; Gilead), branded as Evotaz in both the US and EU. Reyataz is a once-daily boosted PI that is used in combination with other antiretroviral drugs for the treatment of HIV-1 infection. Tybost is a boosting agent to be used in combination with PIs as part of treatment regimens for HIV-1 infection. PIs block the activity of the HIV-1 protease enzyme, which inhibits cleavage of the Gag-Pol polyprotein precursor. This results in the production of immature, non-infectious virus.
Sales of the Reyataz franchise continue to fall due to loss of market share to single-tablet regimens (STRs), as well as to rival drugs Prezista (darunavir; Johnson & Johnson) and Tivicay (dolutegravir; ViiV Healthcare). This sales decline is set to continue due to Reyataz’s relegation to an “alternative” regimen in US and EU guidelines, as well as the approval of Symtuza ([darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)]; Johnson & Johnson), which is the first ever protease inhibitor-based STR for treatment-naïve and treatment-experienced patients.
Analyst Outlook
Sales of the Reyataz franchise, comprising of Reyataz (atazanavir; Bristol-Myers Squibb) and Evotaz ([atazanavir + cobicistat]; BristolMyers Squibb/Gilead), continue to fall due to loss of market share to single-tablet regimens (STRs), as well as to rival drugs Prezista (darunavir; Johnson & Johnson) and Tivicay (dolutegravir; ViiV Healthcare). This sales decline is set to continue due to Reyataz’s relegation to an “alternative” regimen in US and EU guidelines, as well as the approval of Symtuza ([darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)]; Johnson & Johnson), which is the first ever protease inhibitor-based STR for treatmentnaïve and treatment-experienced patients.
The availability of generics in the US (December 2017) and EU (March 2019) has also contributed to a severe drop in sales of Reyataz. While the Evotaz fixed-dose combination (FDC) will afford some protection to the franchise, as physicians are reluctant to increase patients’ pill burdens by providing cheaper generic atazanavir + a boosting agent in separate pills, the franchise’s role in the HIV treatment algorithm will continue to diminish as integrase strand transfer inhibitor (INSTI)-based options increasingly dominate early lines of therapy, and novel, lower-cost two-drug regimens gain uptake in the maintenance setting.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Reyataz franchise : HIV
LIST OF FIGURES
12 Figure 47: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
15 Figure 48: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
16 Figure 49: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
LIST OF TABLES
6 Table 1: Reyataz drug profile
6 Table 2: Evotaz drug profile
7 Table 3: Approval history of Reyataz for HIV in the US, Japan, and five major EU markets
8 Table 4: Late-phase trials of Reyataz for HIV
9 Table 5: Approval history of Evotaz for HIV in the US and five major EU markets
10 Table 6: Late-phase trials of Evotaz for HIV
11 Table 7: Reyataz franchise for HIV – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Atripla 
Sign up to the